ziMyGNCT06055959
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
At risk: Primary completion moved at least 5 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 32 versions: 31 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Primary completion pushed from Nov 16, 2026 to May 12, 2027
- Study completion pushed from Dec 25, 2026 to Jun 22, 2027
- Notable Eligibility criteria expanded, about 11 words
- Secondary endpoints: details revised at 8 of 9 entries
- Site details revised at 1 of 9 sites
- Minor Site details revised at 2 of 9 sitesv30
- Minor Site details revised at 1 of 9 sitesv29
- Minor Site details revised at 1 of 9 sitesv28
Show 25 earlier versionsHide 25 earlier versions
- Minor Site details revised at 1 of 9 sitesv27
- Minor Site details revised at 2 of 9 sitesv26
- Minor Site details revised at 1 of 9 sitesv25
- Minor Site details revised at 1 of 9 sitesv24
- Minor Site details revised at 1 of 9 sitesv23
- Minor Site details revised at 1 of 9 sitesv22
- Minor Site details revised at 1 of 9 sitesv21
- Minor Site details revised at 1 of 9 sitesv20
- Minor Study sites: 8 to 9v19
- Minor Study sites: 7 to 8v17
- Minor Study sites: 6 to 7v16
- Minor Study sites: 5 to 6v15
- Minor Start date changed from estimate of Oct 15, 2024 to Oct 16, 2024v14
- Minor Start date: Sep 16, 2024 to Oct 15, 2024v13
- Notable Start date: Jul 15, 2024 to Sep 16, 2024
- Primary completion date: Oct 26, 2026 to Nov 16, 2026
- Study completion date: Dec 4, 2026 to Dec 25, 2026
- Notable Start date: Jun 11, 2024 to Jul 15, 2024v11
- Minor Study sites: 4 to 5v10
- Notable Start date: May 7, 2024 to Jun 11, 2024v9
- Minor Study sites: 3 to 4v8
- Minor Start date: Apr 25, 2024 to May 7, 2024v7
- Minor Study sites: 1 to 3v6
- Notable Start date: Mar 18, 2024 to Apr 25, 2024v5
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Jan 31, 2024 to Mar 18, 2024
- Study sites: 0 to 1
- Notable Eligibility criteria expanded, about 46 words
- Start date: Jan 2024 to Jan 31, 2024
- Notable Start date: Sep 29, 2023 to Jan 2024v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Plasma concentrations of zilucoplan (ZLP) sampled at Week 4 (Day 29)
Timeframe: Week 4 (Day 29)
Change from Baseline in sheep red blood cell (sRBC) lysis at Week 4 (Day 29)
Timeframe: Week 4 (Day 29)
Change from Baseline in complement component 5 (C5) levels at Week 4 (Day 29)
Timeframe: Week 4 (Day 29)
Secondary (9)
Occurence of treatment-emergent adverse events (TEAEs) during the course of the study
Occurrence of treatment-emergent serious adverse events (TESAEs)
Occurrence of TEAEs leading to permanent withdrawal of investigational medicinal product (IMP)
Occurrence of treatment-emergent infections
Occurrence of antidrug antibody (ADA) and anti- polyethylene glycol (PEG) antibodies at Week 4 (Day 29)
Show 4 moreShow less
Change in MG-activities of daily living (MG-ADL) score from Baseline to Week 4 (Day 29).
Change in Quantitative MG (QMG) score from Baseline to Week 4 (Day 29)
Myasthenia Gravis Foundation of America Post-Interventional Status (MGFA-PIS) at Week 4 (Day 29)
Change in Pediatric Quality of Life Inventory (PedsQoL), Version 4 domain scores from Baseline to Week 4 (Day 29)
Arms and interventions
Zilucoplan ArmExperimental
Study participants will receive zilucoplan in pre-defined dose based on their weight.
Drugs: Zilucoplan
Sites
9 sites in 5 countries
Poland 2, South Korea 2, United Kingdom 2, United States 2, Italy 1